CHAI’s Research and Development (R&D) Team works from a unique angle to support CHAI’s ambitions to improve patient outcomes in low- and middle-income countries. In particular, the team works to: 1. Identify, develop, validate, and transfer for manufacture and distribution better and less expensive drug formulations of existing HIV/AIDS, tuberculosis (TB), and malaria medicines; 2….

ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV London, May 26, 2015 – ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA)…

An agreement announced today will reduce the achievable cost per use of the non-pneumatic anti-shock garment (NASG) by over 75 percent and expand access to this innovative new product, which has been shown to safely and effectively reduce mortality due to post-partum hemorrhage, a leading cause of the nearly 290,000 maternal deaths reported annually around the world.

Clinton Health Access Initiative, Inc. Donor Disclosure Policy – Q & A April 16, 2015 Q: Why is CHAI’s policy different from the Clinton Foundation’s policy? CHAI is an independent 501c3 charitable organization, separate from the Clinton Foundation. CHAI operates in over 30 countries and has nearly 1,500 employees, over 80 percent of whom are…

In 2019, updates to historical datasets were made upon consultation with relevant current suppliers, including the addition of a new supplier’s data. Please find the most up-to-date report here. The 2015 Family Planning Market Report can be found below.  

The U.S. Centers for Disease Control and Prevention (CDC) is leading a consortium of malaria partners aiming to eliminate indigenous cases of malaria on the island of Hispaniola by 2020.

CHAI supports national governments to expand high-quality care and treatment to people living with HIV/AIDS.

HIV viral load testing improves the quality of care for patients on antiretroviral therapy. CHAI partnered with the Government of South Africa, UNAIDS, PEPFAR, Global Fund to Fight AIDS, Tuberculosis and Malaria, and Roche to negotiate a global access price for viral load of US$9.40 per test, which will save more than US$150 million between…

CHAI's Demand-Driven Evaluations for Decisions (3DE) program is a pioneering approach to support ministries in the health sector with evidence-based decision-making by using rigorous impact evaluations in a demand-driven, rapid, and efficient way.